Genmab stock gains as Kempen raises target to DKK 3,300

Published on 09/23/2026 at 12:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock traded at DKK 2,305 on September 23, 2026, as Kempen lifted its target from DKK 2,900 to DKK 3,300. Q2 revenue reached USD 1.16 billion.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab stock traded at DKK 2,305.00 on Nasdaq Copenhagen at 9:35 a.m. on September 23, 2026, up 1.14 percent on the session. The move followed Van Lanschot Kempen's increase of its price target from DKK 2,900 to DKK 3,300, while the firm retained a buy rating, according to MarketScreener on September 23, 2026.

Petosemtamab drives the upgrade

Kempen's new target is DKK 400 higher than its previous target, an increase of 13.8 percent. The analysis identified petosemtamab as a potential major catalyst for Genmab's pipeline, and placed the new target above the other analyst targets cited in the report.

The valuation case is tied to several late-stage clinical milestones. According to Investing.com on September 22, 2026, Genmab expects important readouts in the fourth quarter of 2026 and the first quarter of 2027, including data for petosemtamab and other oncology assets.

Revenue supports the pipeline

Genmab reported second-quarter 2026 revenue of USD 1.16 billion, compared with a consensus estimate of USD 1.12 billion, while adjusted earnings per share came in at USD 0.54 against an estimate of USD 0.37, according to MarketBeat on September 23, 2026. The revenue beat was USD 40 million, while EPS exceeded consensus by USD 0.17.

That earnings base matters because the pipeline is being developed alongside established commercial products. The same September 2026 conference coverage reported that Darzalex and EPKINLY provided meaningful support for second-quarter performance, while specific peak-sales guidance for Rina-S and EPKINLY was deferred until more clinical data become available, according to Investing.com.

Stock remains near yearly high

Genmab's Nasdaq-listed US ADR changed hands at USD 35.22 at the September 23, 2026 closing price shown by MarketBeat, with a 52-week range of USD 23.62 to USD 35.43. The Copenhagen reference share price was DKK 2,305.00 at 9:35 a.m. on September 23, 2026, and the stock had gained 13.81 percent over five trading days in the MarketScreener snapshot.

MarketBeat lists Genmab's market capitalization at USD 21.97 billion and an average ADR price target of USD 39.50. The contrast between Kempen's DKK 3,300 target and the average target shows why the upcoming clinical data are central to the valuation debate rather than a secondary pipeline detail.

Clinical milestones set the next test

Genmab stock traded at DKK 2,305.00 on Nasdaq Copenhagen as of 9:35 a.m. on September 23, 2026. The next valuation test is the Q4 2026 readout schedule, with further petosemtamab data expected in Q1 2027 if the clinical timetable remains on track.